I think you need to check the development agreement again. At the first interim they were to be provided with a yes/no answer to whether the surrogate efficacy endpoints had been met. The only way the DMC would have ended the trial at the first interim was for safety.
The 1Q17 second interim analysis is on the primary endpoints and will have a futility analysis which could stop the trial.
Clearly the purpose of the first interim was to provide an early readout to enable Teva to make a decision on whether to keep funding the trial without deblinding the primary endpoints.
An 'administrative look' is how Silviu described it - not hugely instructive!
Money Week 22/9/16, page-12
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |